Table 1.

Characteristics of the 5 patients with refractory disease included in this study

Patient	Sex	Age (y)	Clinical status at time of drug profiling	Salvage treatment	Current status
1	F	2	Relapsed after SCT, early relapse	MLL:MLLT10-positive; blinatumomab	Alive, follow-up at 15 mo
2	M	7	Relapsed after SCT, second relapse, resistant to anti-CD19 therapy	Blinatumomab, second transplant	Alive, follow-up at 9 mo
3	F	8	Relapsed after SCT, second relapse	Chemotherapy, second transplant	Died
4	F	5	Very early BM relapse	Resistant to blinatumomab, no response to bortezomib combined with 4 drugs	Died
5	F	11	Relapsed after SCT, second (late) relapse	Second transplant, resistant to blinatumomab, partial response to bortezomib combined with 4 drugs	Died

BM, bone marrow; F, female; M, male; SCT, stem cell transplant.